BIRC5 and neurofibroma: In addition, targeted therapy of EGFR/ErbB2 inhibits ErbB2 phosphorylation and Survivin upregulation, as well as downstream ERK1/2 and AKT activation, thereby reducing neurofibroma cell proliferation,39 which is consistent with our results of Survivin downregulation.